Updated safety analysis

2021

General Safety
Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis
Data-cut: November 2020
                      
COVID-19
COVID-19 in people with multiple sclerosis treated with ocrelizumab
Data-cut: May 2021
                      
COVID-19
Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
Publication date: October 2021
                      
Pregnancy
Pregnancy and infant outcomes in women receiving ocrelizumab for the treatment of multiple sclerosis
Data-cut: March 2021
                      
General safety
Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis
Data-cut: January 2020

2020

COVID-19
COVID-19 in ocrelizumab-treated people with multiple sclerosis
Data-cut: July 2020
                      
Vaccines
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study
Data-cut: February 2017
                      
                      
COVID-19
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - a pharmacovigilance case series
Data-cut: April 2020

2019

PML
Cases reported as progressive multifocal leukoencephalopathy in ocrelizumab-treated patients with multiple sclerosis
Data-cut: July 2019.

COVID-19, coronavirus disease 2019; ECTRIMS, European Committee for Treatment and Research in MS; IRRs, infusion-related reactions; PML, progressive multifocal leukoencephalopathy.

M-XX-00007156 (Date of preparation: October 2021)

Prescribing information

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.
Archived data reports for fatalities were last updated February 2021. Please note that there will be no further updates of these archived materials